Shu Yuuei, Winfrey Sarah, Yang Zhi-Yong, Xu Ling, Rao Srinivas S, Srivastava Indresh, Barnett Susan W, Nabel Gary J, Mascola John R
Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Vaccine. 2007 Feb 9;25(8):1398-408. doi: 10.1016/j.vaccine.2006.10.046. Epub 2006 Nov 7.
DNA plasmids and recombinant adenovirus serotype-5 (rAd5) vectors are being studied in human clinical trials as HIV-1 vaccine candidates. Each elicits robust T-cell responses and modest antibody levels. Since protein immunization alone elicits antibody but not CD8 T-cell responses, we studied protein boosting of DNA and rAd5 HIV-1 vaccine vectors. A single Env protein immunization provided a marked boost in antibody titer in guinea pigs primed with either DNA or rAd5 vaccines, and the resulting antibody binding and neutralization levels were similar to those attained after thee sequential protein immunizations. Since both T-cell immunity and neutralizing antibodies are thought to be required for protection against HIV-1, it may be possible to establish a balanced T-cell and antibody response with appropriate vectored vaccines and improve the neutralizing antibody titer with protein boosting.
DNA质粒和重组腺病毒血清型5（rAd5）载体正在作为HIV-1疫苗候选物进行人体临床试验研究。每种载体都能引发强烈的T细胞反应和适度的抗体水平。由于单独的蛋白质免疫只能引发抗体反应而不能引发CD8 T细胞反应，因此我们研究了用蛋白质增强DNA和rAd5 HIV-1疫苗载体的效果。单次Env蛋白免疫显著提高了用DNA或rAd5疫苗免疫的豚鼠的抗体滴度，并且产生的抗体结合和中和水平与三次连续蛋白质免疫后达到的水平相似。由于人们认为T细胞免疫和中和抗体都是预防HIV-1所必需的，因此有可能通过适当的载体疫苗建立平衡的T细胞和抗体反应，并通过蛋白质增强来提高中和抗体滴度。
